News|Videos|November 21, 2026

CORALreef Extension: Enlicitide Sustains LDL-C Reductions in Interim Analysis of OLE

Fact checked by: Ryan Livingston

Christie Ballantyne, MD, discusses 104-week data from this 3-year extension, noting enlicitide’s sustained effects on LDL-C, non-HDL-C, apoB, and Lp(a).

Enlicitide has demonstrated durable LDL-C lowering for 2 years in patients at risk of atherosclerotic cardiovascular disease (ASCVD), according to an interim analysis of the ongoing CORALreef Extension open-label study.1

These data were presented at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago, Illinois, by Christie Ballantyne, MD, chief of cardiology and cardiovascular research and director for cardiometabolic disease prevention at Baylor College of Medicine.1

“One of the most important things after an approval, even with a new therapy that gave us such a large program of phase 3 data, is to collect follow-up data,” Ballantyne told HCPLive in an exclusive interview. “Now we have this extension, and it’s important to note that 87% of the people in the trial wanted to go into the extension – it’s always encouraging when most of the people who are in a trial want to continue getting the therapy.”

CORALreef Extension aims to evaluate the long-term safety and efficacy of enlicitide following its regulatory approval earlier in July 2026. Patients who had completed either the CORALreef Lipids, CORALreef AddOn, or CORALreef HeFH trials were eligible for inclusion, so long as they had overall intervention compliance ≥80% in their respective study. Patients with an ongoing treatment-related adverse event or who had discontinued treatment in the prior study were excluded.2

Patients enrolled in the extension were administered 20 mg of enlicitide decanoate orally once daily. The study’s primary endpoints are the number of patients with ≥1 adverse event (AE) and the number of discontinuations due to AEs, both measured for roughly 3 years. Secondary endpoints include the mean percent change from the parent study’s baseline in LDL-C, non-HDL-C, apolipoprotein B (apoB), and lipoprotein(a) (Lp(a)) at week 8 of the extension study.2

Among the eligible participants from all 3 studies, a total of 2774 opted to enroll in the extension – a total of >87% of the original patient populations. Mean age among these patients was 62.4 years, and 54.9% had prior major ASCVD. Mean exposure during the OLE was 293.9 days, with a total mean exposure of 476.8 days including the parent studies. At the time of the present interim analysis, 1014 patients in the extension had ≥1.74 years of exposure to enlicitide.1

Ballantyne and colleagues saw a mean percent change of -57.5% (95% CI, -58.9 to -56.2) in LDL-C, -51.5% (95% CI, -52.6 to -50.4) for non-HDL-C, -49.8% (95% CI, -50.7% to -48.8%) for apoB, and -27.5% (95% CI, -28.1 to -25.8) in Lp(a) from parent-study baseline until week 8 of the extension. LDL-C reductions were sustained through 104 weeks from the parent-study baseline, and discontinuations due to AEs were low throughout this period (1.6%). No drug-related serious AEs were reported, and no individual AEs occurred in ≥5% of patients.1

Ultimately, Ballantyne and colleagues concluded that these data reinforce the efficacy and safety profile of enlicitide in this patient population. The limited data from the extension are reassuring and further underscore the value of this therapy for the reduction of a metric that is notoriously difficult to lower and sustain. Additionally, Ballantyne highlights that the extension study will continue, expecting similarly positive results for the remainder of the 3-year study period.1

“We’re always interested in outcome studies, and the outcomes trial has a mixture of both primary and secondary prevention, and there’s a lot of keen interest there since there’s been some data suggesting that there’s a greater relative risk reduction with primary prevention than secondary,” Ballantyne said. “It’ll be interesting to see what this data looks like. And, obviously, when you have a larger study for long periods of time, then you can also see if there are any safety signals that we didn’t see in the smaller studies.”

Editors’ Note: Ballantyne reports disclosures with Abbott, Amgen, Arrowhead, AstraZeneca, Eli Lilly, Genentech, and others.

References
  1. Ballantyne C, Parham J, Carrillo J, et al. Long-Term Efficacy and Safety of Enlicitide in an Open-Label Extension Study. Presented at the American Heart Association (AHA) Scientific Sessions 2026, Chicago, IL. November 6-9, 2026.
  2. Merck Sharp & Dohme LLC. Open-label Extension Study of Enlicitide Decanoate (MK-0616/​Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension. ClinicalTrials.gov Identifier: NCT06492291. Updated October 7, 2025. Accessed November 20, 2026. https://clinicaltrials.gov/study/NCT06492291?term=NCT06492291&rank=1

Related to this article